Synmosa Biopharma (4114) — Financial Flexibility Index
Synmosa Biopharma (4114) has a Financial Flexibility Index of 0.06x as of December 2025. Free cash flow of NT$245.19 Million (operating CF NT$185.72 Million minus capex NT$59.46 Million) represents 0% of total liabilities (NT$3.89 Billion). Check 4114 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Synmosa Biopharma Financial Flexibility Index (2015–2025)
Historical Financial Flexibility Index trend for Synmosa Biopharma across 11 annual periods. For the full cash flow conversion analysis, see 4114 cash flow metrics.
Annual Financial Flexibility Index for Synmosa Biopharma (2015–2025)
Year-by-year free cash flow to debt coverage for Synmosa Biopharma. Explore how well can Synmosa Biopharma service its debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.18x | NT$692.71 Million | NT$411.57 Million | NT$3.89 Billion | ▼ -33.7% |
| 2024 | 0.27x | NT$1.05 Billion | NT$780.62 Million | NT$3.91 Billion | ▲ +24.8% |
| 2023 | 0.22x | NT$781.70 Million | NT$511.93 Million | NT$3.63 Billion | ▲ +29.2% |
| 2022 | 0.17x | NT$759.54 Million | NT$630.25 Million | NT$4.55 Billion | ▲ +31.0% |
| 2021 | 0.13x | NT$537.35 Million | NT$444.29 Million | NT$4.22 Billion | ▲ +37.7% |
| 2020 | 0.09x | NT$408.81 Million | NT$254.40 Million | NT$4.42 Billion | ▲ +161.4% |
| 2019 | 0.04x | NT$138.49 Million | NT$-44.88 Million | NT$3.92 Billion | ▼ -67.3% |
| 2018 | 0.11x | NT$330.43 Million | NT$16.00 Million | NT$3.06 Billion | ▲ +169.6% |
| 2017 | 0.04x | NT$141.74 Million | NT$-5.19 Million | NT$3.54 Billion | ▼ -85.2% |
| 2016 | 0.27x | NT$660.40 Million | NT$236.48 Million | NT$2.44 Billion | ▲ +8.9% |
| 2015 | 0.25x | NT$392.86 Million | NT$23.60 Million | NT$1.58 Billion | — |